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Abstract
Background: Surveillance for HIV transmitted drug resistance (TDR) is performed using HIV genotype results from individual
specimens. Pyrosequencing, through its massive parallel sequencing ability, can analyze large numbers of specimens
simultaneously. Instead of using pyrosequencing conventionally, to sequence a population of viruses within an individual,
we interrogated a single combined pool of surveillance specimens to demonstrate that it is possible to determine TDR rates
in HIV protease from a population of individuals.
Methodology/Principal Findings: The protease region from 96 treatment naı ¨ve, HIV+ serum specimens was genotyped
using standard Sanger sequencing method. The 462 bp protease amplicons from these specimens were pooled in
equimolar concentrations and re-sequenced using the GS FLX Titanium system. The nucleotide (NT) and amino acid (AA)
differences from the reference sequence, along with TDR mutations, detected by each method were compared. In the
protease sequence, there were 212 nucleotide and 81 AA differences found using conventional sequencing and 345
nucleotide and 168 AA differences using pyrosequencing. All nucleotide and amino acid polymorphisms found at
frequencies $5% in pyrosequencing were detected using both methods with the rates of variation highly correlated. Using
Sanger sequencing, two TDR mutations, M46L and I84V, were each detected as mixtures at a frequency of 1.04% (1/96).
These same TDR mutations were detected by pyrosequencing with a prevalence of 0.29% and 0.34% respectively.
Phylogenetic analysis established that the detected low frequency mutations arose from the same single specimens that
were found to contain TDR mutations by Sanger sequencing. Multiple clinical protease DR mutations present at higher
frequencies were concordantly identified using both methods.
Conclusions/Significance: We show that pyrosequencing pooled surveillance specimens can cost-competitively detect
protease TDR mutations when compared with conventional methods. With few modifications, the method described here
can be used to determine population rates of TDR in both protease and reverse transcriptase. Furthermore, this pooled
pyrosequencing technique may be generalizable to other infectious agents where a survey of DR rates is required.
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Introduction
Surveillance of transmitted HIV drug resistance (TDR) is an
essential public health component of a comprehensive HIV
strategy. Information obtained from TDR surveillance facilitates
individual drug selection, where there are many available
combinations, and informs drug selection for national treatment
programs in resource-limited settings[1–3]. TDR surveillance may
be performed through comprehensive surveillance or through
structured sampling methods [4]. Independent of the approach,
TDR surveillance relies upon individual genotyping of surveillance
specimens using Sanger sequencing. Drawbacks intrinsic to
conventional Sanger sequencing are the variable subjective
interpretations of sequencing results, limited sensitivity for minor
sequence variants, and cost. Any technique that removes
subjective interpretation, enhances sensitivity, and has the
potential to lower costs would assist with global HIV TDR
surveillance.
Pyrosequencing provides massive parallel sequencing that can
be used to produce complete genome coverage from a conserved
sequence or create an array of reads from mixed sequences[5,6].
Among heterogeneous collections of sequences, the current
applications of pyrosequencing have been to, either resolve the
sequences from different organisms in the sample[7,8] or be used
to probe extremely low frequency variants existing within a single
target[9–12]. Within HIV genetics, there has been a great deal of
interest in the application of pyrosequencing to address questions
oriented around the genetic diversity of the virus within an
individual. Instead of using the strengths of pyrosequencing to
sequence a population of viruses from within an individual, we
exploited the technique to determine the sequences of viruses from
within a population of individuals. As a proof of concept that this
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9263approach can be used to determine the prevalence of surveillance
TDR mutations, we pyrosequenced an equimolar pool of HIV
protease amplicons from a drug naı ¨ve HIV infected population
and determined rates of protease TDR.
Materials and Methods
Subjects and Specimens
Ninety-six anonymized, remnant serum specimens from an IRB
approved national HIV TDR surveillance program were used in
the analysis. Previous work had shown that the specimen subtypes
were 90 subtype B; 4 subtype C, and one each of A1 and
CRF02_AG. HIV-1 subtypes were determined using REGA HIV-
1 Automated Subtyping Tool based upon pol sequences (http://
www.bioafrica.net/virus-genotype/html/subtyping.html).
Bulk Sanger Sequencing-Based HIV-1 DR Genotypic Test
HIV-1 nucleic acid was extracted from 200 ml of serum using
the Nuclisens EasyMag system (Biomerieux, Canada) following
manufacturer’s instructions. HIV-1 protease (PR) and reverse
transcriptase (RT), up to codon 236, were bidirectional sequenced
with an in-house protocol. Briefly, viral RNA was reverse
transcribed and amplified according to the manufacturer’s direc-
tions using the QIAGEN one-step RT-PCR kit (QIAGEN,
Canada). RT-primers were POF 59-TGAARGAITGYACTGAR-
AGRCAG GCTAAT-39 and POR 59-CCTCATTYTTGCA-
TAYTTYCCTGTT-39 with nested primers PIF 59- YTCAGAR-
CAGRCCRGARCCAACAGC-39 and PIR 59-GGYTCTTGR-
TAAATTTGRTATGTCCA-39. All reactions were carried out
using standard conditions with annealing temperatures of 53uC.
PCR amplicons were then purified and diluted to 15 ng/ml for
DNA sequencing using ABI Prism BigDye 3.1 Cycle Sequencing
System (Applied Biosystems, USA) following manufacturer’s
instructions. The sequencing PCR primers included both nested
PCR primers and two additional primers PS1 59-CTGGTGTYT-
CATTRTTKRTACTAGGT-39 and PS2 59-TTYTGGGARG-
TYCARY TAGGRATACC-39.
Pyrosequencing
Briefly, a 462 nucleotide fragment containing the entire PR
gene was produced by amplifying RT-PCR products using PIF-p
59-TCCCTCARATCACTCTTTGG-39 and PIR-p 59-GGRTT-
TTYAGGCCCAATTTT-39 with an annealing temperature of
59uC. Individual PCR products were purified using Millipore’s
Amicon Microcon-PCR Centrifugal filter devices (Millipore,
USA), pooled in equimolar amount with Beckman Biomex FX
system equipped with a DTX880 Multimode Detector (Beckman,
USA), and sequenced using the GS FLX Titanium pyrosequen-
cing kit (Roche Applied Science. USA). Pyrosequencing of the 96
specimens was conducted using 1/16 the capacity of a full
PicoTiterPlate. Overall the reaction produced 42,928 sequence
reads. Further analysis was only performed on the 19,106 (44.5%)
reads that were: passed by the quality control software; of sufficient
read length to cover the amplicon and; successfully mapped to the
HXB-2 reference sequence. Based on the approximation of the
expected pyrosequencing read length (400,500 bp) and our
template size (462 bp), the mapping criteria was 60% overlapping
and 75% matching to the reference.
The frequency of differences from HIV-1 HXB2 (Accession
number: K03455) was calculated for all pyrosequencing reads.
The polymorphism and DR rates obtained from the pooled
pyrosequencing reads were then compared with the polymorphism
and DR rates calculated from the Sanger sequencing reads. Initial
comparisons were done for all detected polymorphisms including
those present at an extremely low levels. Analysis was repeated on
those polymorphisms that were present at frequencies $0.2%.
This threshold was chosen to be comparable with the sensitivity of
Sanger sequencing based on the following assumptions: under
ideal circumstances bulk, Sanger sequencing can detect a 20%
mixture; the pool of specimens will consist of 100 specimens; thus,
a 20% mixture in a single specimen will be present in the 96-
member pyrosequencing pool at 0.2%.
Sequence Analysis and HIV-1 DR Mutation Determination
Conventional sequences were assembled and edited in Seqscape
v2.5 (Applied Biosystems, USA) with sequence variations identified
by aligning the sequences with HXB-2 (Accession number:
K03455). All polymorphisms/mutations were confirmed through
agreement of bidirectional sequencing results. The 19,106 valid
pyrosequencing reads were aligned with HXB-2 and the frequency
and distribution of nucleotide and AA changes determined using
an in-house Perl script. TDR mutations were identified using a
surveillance drug resistance mutation (SDRM) list [3] with
additional clinical protease mutations identified according to the
IAS-USA HIV DR mutation list [13]. The prevalence of
polymorphisms, TDR and clinical mutations in HIV PR region
were identified using conventional and pyrosequencing methods
and the results compared.
Phylogenetic Analysis
Phylogenetic analysis was performed on the group of pyrose-
quencing reads, containing the TDR mutation of interest, in a
background of the 96 sequences obtained from Sanger sequencing.
Trees were constructed using Neighbor-Joining approach using
the K-2-P model with 100 bootstrap replicates as implemented in
MEGA 4.0[14].
Results
Concordance of the Detection of NT and AA Variations Is
Proportional to Their Frequency
Using conventional Sanger sequencing-based genotypic DR test
satisfactory results were obtained from all 96 specimens. Among all
of the genotypes, a total of 212 nucleotide (NT) and 81 amino acid
(AA) differences from HXB-2 were identified in the PR region.
The 19,106 satisfactory pyrosequencing reads (average length:
437) represented an average redundancy of 17,911 for each
nucleotide locus. Statistically, each base position of every cons-
tituent specimen in the pooled mixture was oversampled 187
times. Analysis of all of the reads demonstrated an aggregate of
1173 NT and 995 AA differences from HXB2. Re-analysis of the
data, identifying only those variations present at a level of $0.2
revealed 345 NT and 168 AA differences from the reference. The
numbers of sequence variations detected and categorized accord-
ing to the frequency of detection by pyrosequencing are shown in
Table 1. All NT and AA changes detected by Sanger sequencing
were identified by pyrosequencing with the latter method showing
a greater ability to detect low abundance variants.
The concordance rates between methods, for detecting NT and
AA changes, were proportional to their abundances in the viral
population (Figure 1). All NT changes present at levels of $5%
were identified by both methods with Sanger sequencing
identifying 96.6% and 24% of the polymorphisms identified by
pyrosequencing at the 1,5%, and 0.2,1% levels respectively.
Similarly, the concordance rate for AA changes was 100% for
those variations present at levels of $5%, 78.4% for those at
1,5%, and 11.6% for those detected in less than 1% of the
pyrosequencing reads. Discrepancies in the frequency of identified
454 in HIV DR Surveillance
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frequency variants detected by pyrosequencing. Furthermore,
these low frequency variants represented the majority of
differences from the reference with 92.7% of NT and 96.4% of
AA changes present at less than 5% and 85.3% of NT and 92.7%
of AA variations occurring in less than 1% of the reads.
Proportional Representation of Detected NT and AA
Variants
Comparison of the measured frequency of variants by
pyrosequencing, or the calculated frequency of variants by Sanger
sequencing, showed that both methods produced comparable
results across a range of frequencies (Table 1). The greatest
discrepancies between the two methods were identified at the
extreme frequency ranges (,1% or $30%) and where variants
were found at the termini of pyrosequenced fragments.
Detection of HIV Protease DR Mutations
Thirteen protease TDR mutations were detected by pyrose-
quencing at frequencies ranging from 0.20% to 0.64% (Table 2).
Two of these TDR mutations: M46L and I84V, detected at
frequencies of 0.29% and 0.34% respectively, were also found in
two Sanger sequences as mixed base calls (Figure 2). We
performed a phylogenetic analysis using pyrosequencing reads
containing individual TDR mutations in a background of the 96
Table 1. Sequence variations detected by pyrosequencing and Sanger sequencing- based genotypic DR test.
Variation Frequency (%)
a Nucleotide Variations Amino acid variations
Pyrosequencing Sanger sequencing
b D % (ABS6SD)
c Pyrosequencing
Sanger
sequencing
D %
(ABS6SD)
c
0.2,0.49 132 17 0.760.1 81 9 0.760.1
0.5,0.99 40 24 0.360.3 14 2 0.360.0
1,4.99 87 84 0.860.8 37 29 0.861.0
5,9.99 47 47 1.661.8 21 21 1.861.6
10,14.99 14 14 2.361.6 4 4 3.062.2
15,19.99 6 6 1.861.9 1 1 3.78
20,29.99 9 9 5.366.1 3 3 2.062.6
.=30% 10 10 6.1610.4 7 7 2.261.5
a: The categorization of frequencies based on the frequencies of variations identified by pyrosequencing;
bNumber of nucleotide and amino acid variation listed under Sanger sequencing is the sum of all variants identified in the Sanger sequences that were detected by
pyrosequencing at the given frequency;
c: Absolute value of the difference in variation frequency of nucleotide (NT) or amino acid (AA) frequency between the two approaches for concordantly detected mutations
(Mean6 standard deviation).
doi:10.1371/journal.pone.0009263.t001
Figure 1. Concordance of variations detection by pyrosequen-
cing and Sanger sequencing. The concordance rates were
calculated as percentage of pyrosequencing detected sequence
variations that were also observed in Sanger sequencing. Frequency
ranges are categorized based on those detected by pyrosequencing.
doi:10.1371/journal.pone.0009263.g001
Table 2. HIV-1 protease DRMs identified by pyrosequencing
and Sanger sequencing.
Protease TDR Mutations
(WHO SDRM)
Minor Protease DRMs
(IAS-USA 2008)
Mutations
%
(Sanger)
%
(Pyro) Mutations
%
(Sanger)
%
(Pyro)
M46L 1.04 0.29 L10V 4.17 5.03
I84V 1.04 0.34 G16E 6.25 4.95
M46I 0 0.35 K20R 0 0.64
D30N 0 0.22 K20I 2.08 1.74
I47V 0 0.27 L33I 2.08 2.31
I50V 0 0.58 L33V 6.25 7.42
F53L 0 0.64 M36I 19.79 14.06
I54T 0 0.24 D60E 10.42 10.84
G73S 0 0.20 I62V 22.92 23.07
V82A 0 0.47 I64M 1.04 1.22
I85V 0 0.25 I64L 5.21 6.30
N88D 0 0.35 I64V 11.46 7.60
N88S 0 0.48 H69K 11.46 9.66
A71T 10.42 6.63
A71V 8.33 10.44
V77I 33.33 35.78
V82I 1.04 1.46
I93L 62.50 62.43
doi:10.1371/journal.pone.0009263.t002
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ingly clustered with the appropriate Sanger sequences that had the
mixtures identified on the electropherograms (Figure 3). Among
those TDR detected by pyrosequencing but not detected by
Sanger sequencing, two distinct patterns emerged. In the first case,
there was a clear association of pyrosequencing reads with single
Sanger sequences; however, the absolute number of associated
reads was much lower than in situations in which corresponding
mutations were seen in the Sanger reads (Figure 4a). In the
second case, the phylogenetic analysis did not demonstrate any
significant association of the pyrosequencing reads with any single
Sanger sequences (Figure 4b). These results are representative of
all examined DR mutations as well as those variations at non-
DRM sites detected by pyrosequencing only (Data Not Shown).
Except for K20R which was detected by pyrosequencing only,
17 clinical, minor protease DR mutations were detected by both
methods with extremely high concordance across a broad range of
rates (Figure 5). Phylogenetic analysis using pyrosequencing reads
containing specific minor protease mutations again showed that
these reads overwhelmingly clustered with the correct number of
Sanger sequences containing the concordant mutations. There are
six clusters of pyrosequencing reads that cluster around the six
L33V mutant sequences detected by Sanger sequencing
(Figure 6a). The L33I was detected in only two Sanger reads
and correspondingly the majority of the pyrosequencing reads
containing the same mutation cluster around those two sequences
(Figure 6b).
Discussion
Successful TDR surveillance programs typically acquire se-
quencing results from large numbers of antiretroviral naı ¨ve
subjects and produce an estimate of the percentage of drug
resistance based upon the aggregate results. The percentage
resistance to protease inhibitors is not described in the context of
the individual but instead is attributed to the population under
study. Thus far, pyrosequencing of HIV has been used to explore
HIV DR in a population of viruses within an individual
Figure 2. Bidirectional sequence electropherograms for the
two TDR mutations detected by conventional Sanger sequenc-
ing. Two TDR mutations, M46L and I84V, were detected by
conventional Sanger sequencing, each in one of the 96 examined
specimens. Electropherograms demonstrate that both mutations
existed as a component of a mixture.
doi:10.1371/journal.pone.0009263.g002
Figure 3. Phylogenetic analysis on pyrosequencing reads with SDRMs detected in bulk, Sanger sequencing. All positive
pyrosequencing reads containing M46L (a) and I84V (b) were analyzed with Sanger sequences from the 96 specimens using Neighbour-Joining
(K-2-P) with 100 bootstraps. The pyrosequencing reads with corresponding SDRM are shown in blue with the 96 Sanger sequences shown in red.
doi:10.1371/journal.pone.0009263.g003
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pyrsosequencing on pooled specimens in order to survey for
protease DRM contained in viruses within a population.
The findings presented here are strongly supportive of analyzing
pooled specimens for the determination of the prevalence of HIV
TDR in HIV PR. The concordance of DRM detection when the
results from PR sequencing were analyzed is astonishing. At a
mutation level detected by pyrosequencing of greater than 5%,
there is a 100% concordance of the prevalence of specific NT or
AA changes. The overall correlation between all protease DR
mutations between methods is similarly impressive. In situations
where the mutations were present at frequencies greater than 1%,
phylogenetic analysis demonstrated that there were a discrete
number of clusters that corresponded to the number of Sanger
sequences with that mutation. This finding further demonstrates
that the results from pooled pyrosequencing reflect the bulk
sequence content of the constituent specimens.
Determining the protease TDR prevalence using dendograms
derived from the pyrosequencing reads presented an interesting
challenge. Pyrosequencing reads of both the SDR mutations,
M46L and I84V, identified by Sanger sequencing, were found be
tightly clustered and almost exclusively associated with the mutant
Sanger sequences. These mutations were detected as 0.29% and
0.34% of the total number of reads consistent with their presence
as mixtures in the bulk Sanger sequence. The dendograms for the
M46L and I84V mutations detected by pyrosequencing were
unique among those SDRM found at frequencies of less than 1%.
With further validation, this pattern of clustering may allow one to
reproducibly identify those mutations that would also be observed
as mixtures in Sanger sequences. We also observed cases where
there were only a few mutant pyrosequencing reads but they were
related, and they also clustered with a specific Sanger sequence.
We believe that the observed mutant reads reflect minority
variants undetectable by bulk sequencing methodology. Finally,
there were the occasional mutant pyrosequencing reads that were
not clearly associated with any single sequences and these may
represent PCR artifact only. Further studies will confirm the
predictive value of phylogenetic patterns of pyrosequencing reads
but one implication is that thresholds for calling mixtures in TDR
surveillance need to be standardized.
Figure 4. Phylogenetic analysis of pyrosequencing reads with SDRMs not detected by bulk Sanger sequencing. All positive
pyrosequencing reads containing M46I (a) and F53L (b) were analyzed with Sanger sequences from the 96 specimens using Neighbour-Joining (K-2-
P) with 100 bootstraps. The pyrosequencing reads with corresponding SDRM are shown in blue with the 96 Sanger sequences shown in red. Clusters
of pyrosequencing reads are indicated with a green circle.
doi:10.1371/journal.pone.0009263.g004
Figure 5. Consistent and comparable frequency readouts for
minor protease DRMs by the two approaches. Eighteen minor DR
mutations (IAS-USA 2008) were detected by either pyrosequencing or
Sanger sequencing among the 96 specimens. Individual mutations are
plotted against thee frequency detected by each Chart shows the
frequency at which the individual mutations were detected by each
method.
doi:10.1371/journal.pone.0009263.g005
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counting TDR mutations arising from a single specimen was
addressed in this study. After reviewing 803 pyrosequencing reads
with TDR mutations in PR, we found 38 reads that contained
more than one drug resistance mutation (DRM) in this region.
The reads with more than one mutation were not associated with
any one single DRM and occurred in less than 5% of the mutant
reads. Thus, the absolute contribution of a multiply drug resistant
specimen to the final results is negligible.
Future studies that would allow for reporting on linked
mutations that exist in one coding region, or linked mutations in
different coding regions in pol, will require some means of
associating individual pyrosequencing reads. In fact in this study,
the observation of high rates of non-SDRM protease mutations is
entirely consistent with single specimens harbouring multiple
DRMs. Methods have been described for constructing haplotypes
from pyrosequencing reads using computational methods[15];
however the ability to implement these techniques in a population
of 96 different viruses is unknown. Using multiplex identifiers
would not only allow for TDR surveillance of mutations within
protease and reverse transcriptase but also facilitate recognition of
multiple linked DRM within a single specimens[15]. Current
multiplex identifier techniques for pyrosequencing allow identifi-
cation of 151 separate specimens which is more than sufficient for
a surveillance study on the scale of threshold survey [16,17].
To further evaluate the application potential of pyrosequencing
in HIV DR surveillance, we calculated and compared the material
and labor costs for Sanger sequencing and pyrosequencing (Table
S1, S2 and S3). For these calculations it was assumed that the
respective instruments were embedded, as components of an
institutional core facility, as would be expected for a laboratory
capable of performing specialized HIV DR testing. The combined
labour and material costs of HIV genotyping using our in-house
Sanger sequencing method was $82/specimen which is less than
half the cost of commercial genotyping. Due to the common steps
involved, the cost of determining drug resistance in protease is not
halved but falls to $52/specimen (Table S3). In comparison, the
total cost for the equivalent analysis of protease using pyrosequen-
cing was $32/specimen. For pooled pyrosequencing based
surveillance of TDR in protease and reverse transcriptase,
assuming sequencing of three overlapping regions, costs are
predicted to be $53/specimen (Table S3). These calculations
include costs for the additional labour required for pyrosequen-
cing. Pyrosequencing costs may, in fact, continue to fall due to
competition and the increased market penetrance of these newer
platforms. With competitive costs and the existing scaling, the
pooled pyrosequencing approach may be useful in global TDR
surveillance through its implementation at specialized HIV DR
laboratories [17].
Although pyrosequencing pooled specimens is a promising
approach for TDR surveillance, there are limitations to extrap-
olating the results from our study. The high sensitivity and data
throughput of pyrosequencing result in high number of NT
variants being detected, many of which exist at low frequencies.
The phylogenetic analysis is helpful in resolving this issue but
further improvements will be obtained by using the multiplex
identifier approach. Second, in order to accurately reflect the true
TDR prevalence in the viral population, the PCR amplicons from
each component specimen need to be pooled at equimolar
concentrations with extreme precision. Any bias introduced at this
step can have a significant effect on reported TDR prevalence.
Third, although high numbers of sequence reads are generated for
each pyrosequencing run, the quality and usability of these reads
vary. Stringent sequence alignment criteria are essential to screen
out unreliable shorter reads and those containing false insertion/
deletion mutations.
Figure 6. Phylogenetic analysis on pyrosequencing reads with minor DRMs and Sanger sequences from all 96 pooled specimens. All
positive pyrosequencing reads containing L33V (a) and L33I (b) were analyzed with Sanger sequences from the 96 specimens using Neighbour-
Joining (K-2-P) with 100 bootstraps. The pyrosequencing reads with corresponding SDRM are shown in blue with the 96 Sanger sequences shown in
red. Clusters of pyrosequencing reads are indicated with a green circle.
doi:10.1371/journal.pone.0009263.g006
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of the HIV protease identifies protease TDR mutations with
comparable costs to conventional Sanger sequencing. Pyrosequen-
cing results were highly correlated with those produced by
conventional Sanger sequencing of individual specimens. Advanc-
es in labeling of pyrosequencing specimens will facilitate linkage
TDR mutations across the pol gene making it possible to use this
approach for TDR surveillance for mutations in both protease and
reverse transcriptase. The significance of minor sequence variants,
which exist within individuals in surveillance cohort but below the
detection threshold of conventional techniques, remains to be
explored. Applications for this technique may be found in other
disciplines where surveillance of mutations within a population is
required.
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